Ident. | Authors (with country if any) | Title |
---|
002291 |
Francisco Grandas [Espagne] ; Jaime Kulisevsky [Espagne] | Treatment of Parkinson's disease in Spain |
002318 |
Tomoyuki Uchiyama [Japon] ; Ryuji Sakakibara [Japon] ; Takamichi Hattori [Japon] ; Tomonori Yamanishi [Japon] | Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon |
002343 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor |
002391 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
002429 |
Birgit Hogl [Autriche] ; Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Susanne Glatzl [Autriche] ; Birgit Frauscher [Autriche] ; Ulrike Niedermüller [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Increased daytime sleepiness in Parkinson's disease: A questionnaire survey |
002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
002467 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
002471 |
Gregorio Segovia [Royaume-Uni, Espagne] ; Francisco Mora [Espagne] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease |
002472 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson ; Matthew J. Hansard ; Eleni Maratos ; Peter Jenner | Effect of pulsatile administration of Levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
002477 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest Tremor and UPDRS part III in Parkinson's disease |
002518 |
Cathy Chuang [États-Unis] ; Anne Constantino [États-Unis] ; Casilda Balmaceda [États-Unis] ; David Eidelberg [États-Unis] ; Steven J. Frucht [États-Unis] | Chemotherapy-induced Parkinsonism responsive to levodopa: An underrecognized entity |
002519 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
002532 |
Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas] | Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks |
002545 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; JING XIE [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease |
002553 |
| Management of Parkinson's disease: an evidence-based review |
002556 |
Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
002573 |
Manavdeep Grewal [Canada] ; Raed Hawa [Canada] ; Colin Shapiro [Canada] | Treatment of periodic limb movements in sleep with selegiline HCl |
002582 |
Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni] | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets |
002585 |
Louis C. Tan [États-Unis] ; Peter H. Protell [États-Unis] ; J. William Langston [États-Unis] ; Daniel M. Togasaki [États-Unis] | The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced Abnormal Movements in squirrel monkeys |
002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
002631 |
Robert A. Hauser [États-Unis] ; Nicholas H. G. Holford [Nouvelle-Zélande] | Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's Disease |
002653 |
Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis] | Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease |
002666 |
Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie] | Paradoxical response to apomorphine in a case of atypical parkinsonism |
002671 |
Ruth Djaldetti [Israël] ; Rivkah Inzelberg [Israël] ; Nir Giladi [Israël] ; Amos D. Korczyn [Israël] ; Yehudit Peretz-Aharon [Israël] ; Martin J. Rahey [Israël] ; Yuval Herishano [Israël] ; Silvia Honigman [Israël] ; Sami Badarny [Israël] ; Eldad Melamed [Israël] | Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease |
002686 |
Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie] | Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease |
002700 |
| MAO-B inhibitors for the treatment of Parkinson's disease |
002705 |
| Levodopa |
002706 |
Miriam Velez [Pérou] ; Carlos Cosentino [Pérou] ; Luis Torres [Pérou] | Levodopa-responsive rubral (Holmes') tremor |
002707 |
Gurutz Linazasoro [Espagne] ; Nadege Van Blercom [Espagne] ; Asier Lasa [Espagne] | Levodopa-induced ocular dyskinesias in Parkinson's disease |
002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
002709 |
Jong-Min Kim [Corée du Sud] ; KI HYEONG LEE [Corée du Sud] ; Yoon-La Choi [Corée du Sud] ; GI YEONG CHOE [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy |
002710 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
002727 |
Valerie E. Kelly [États-Unis] ; Allie S. Hyngstrom [États-Unis] ; Melissa M. Rundle [États-Unis] ; Amy J. Bastian [États-Unis] | Interaction of levodopa and cues on voluntary reaching in Parkinson's disease |
002728 |
Luc J. P. Defebvre [France] ; Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Alain Duhamel [France] ; Jean-Louis Bourriez [France] ; Myriame Perina [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France] | Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease |
002765 |
J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study |
002770 |
Alexander Fisher [Australie] ; James Croft-Baker [Australie] ; Michael Davis [Australie] ; Patrick Purcell [Australie] ; Allan J. Mclean [Australie] | Entacapone-induced hepatotoxicity and hepatic dysfunction |
002771 |
Ashfaq A. Sharif [États-Unis] | Entacapone in restless legs syndrome |
002780 |
Julie A. Robichaud [États-Unis] ; Kerstin D. Pfann [États-Unis] ; Cynthia L. Comella [États-Unis] ; Daniel M. Corcos [États-Unis] | Effect of medication on EMG patterns in individuals with Parkinson's disease |
002792 |
Oleh Hornykiewicz [Autriche] | Dopamine miracle: From brain homogenate to dopamine replacement |
002794 |
Chin-Song Lu [Taïwan] ; Yah-Huei Wu Chou [Taïwan] ; Tzu-Chen Yen [Taïwan] ; Chon-Haw Tsai [Taïwan] ; Rou-Shayn Chen [Taïwan] ; Hsiu-Chen Chang [Taïwan] | Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2 |
002797 |
J. E. Rice [Australie] ; R. Antic [Australie] ; Philip D. Thompson [Australie] | Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease |
002807 |
Diego Garcia-Borreguero [Espagne] ; Ana B. Caminero [Espagne] ; Yolanda De La Llave [Espagne] ; Oscar Larrosa [Espagne] ; Soledad Barrio [Espagne] ; Juan J. Granizo [Espagne] ; Juan A. Pareja [Espagne] | Decreased phasic EMG activity during Rapid eye movement sleep in treatment-naïve Parkinson's disease: Effects of treatment with levodopa and progression of illness |
002808 |
| DA agonists: ergot derivatives: Bromocriptine |
002809 |
| DA agonists: Non-Ergot derivatives: Ropinirole |
002810 |
| DA agonists: Non-Ergot derivatives: Pramipexole |
002811 |
| DA agonists: Non-Ergot derivatives: Piribedil |
002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
002813 |
| DA agonists: Ergot derivatives: Pergolide |
002814 |
| DA agonists: Ergot derivatives: Lisuride |
002815 |
| DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC) |
002816 |
| DA agonists: Ergot derivatives: Cabergoline |
002826 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
002834 |
Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Characterisation of striatal NMDA receptors involved in the generation of Parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat |
002838 |
Jakob Christensen [Danemark] ; Erik Dupont [Danemark] ; Karen Stergaard [Danemark] | Cabergoline plasma concentration is increased during concomitant treatment with itraconazole |
002839 |
| COMT inhibitors |
002847 |
Francesc Valldeoriola [Espagne] ; Manuela Pilleri [Espagne] ; Eduardo Tolosa [Espagne] ; José L. Molinuevo [Espagne] ; Jordi Rumia [Espagne] ; Enric Ferrer [Espagne] | Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Long-term follow-up of patients |
002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
002859 |
| Anticholinergic therapies in the treatment of Parkinson's disease |
002863 |
| Amantadine and other antiglutamate agents |
002867 |
Marcelo Merello [Argentine] ; Maria I. Nouzeilles [Argentine] ; Gabriel Piran Arce [Argentine] ; Ramon Leiguarda [Argentine] | Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis |
002902 |
Elan D. Louis [États-Unis] ; Linda Winfield [États-Unis] ; Stanley Fahn [États-Unis] ; Blair Ford [États-Unis] | Speech dysfluency exacerbated by levodopa in Parkinson's disease |
002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
002927 |
Anette Schrag [Royaume-Uni] ; Michael Trimble [Royaume-Uni] | Poetic talent unmasked by treatment of Parkinson's disease |
002946 |
J. Hoenicka [Espagne] ; L. Vidal [Espagne] ; M. Godoy [Espagne] ; J. J. Ochoa [Espagne] ; J. Garcia De Yebenes [Espagne] | New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism |
002949 |
P. H. Gordon [États-Unis] ; S. J. Frucht [États-Unis] | Neuroleptic malignant syndrome in advanced Parkinson's disease |
002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
002964 |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
002966 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie] | Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life |
002971 |
Birgit Högl [Autriche] ; Md. Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy: Placebo-controlled, polysomnographic case report |
002973 |
Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie] | Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study |
002997 |
J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis] | Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature |
002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
002A36 |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions |
002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
002A67 |
J. I. Hoff [Pays-Bas] ; A. A. V. D. Plas [Pays-Bas] ; E. A. H. Wagemans [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] | Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease |
002A78 |
C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis] | Waking up to sleep episodes in Parkinson's disease |
002A92 |
R. A. Hauser [États-Unis] ; W. C. Koller [États-Unis] ; J. P. Hubble [États-Unis] ; T. Malapira [États-Unis] ; K. Busenbark [États-Unis] ; C. W. Olanow [États-Unis] | Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease |
002A95 |
L. M. Shulman [États-Unis] ; A. Minagar [États-Unis] ; A. Rabinstein [États-Unis] ; W. J. Weiner [États-Unis] | The use of dopamine agonists in very elderly patients with Parkinson's disease |
002A96 |
Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
002B05 |
I. Reuter [Royaume-Uni] ; S. Harder [Allemagne] ; M. Engelhardt [Allemagne] ; H. Baas [Allemagne] | The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa |
002B22 |
N. A. Leopold [États-Unis] | Risperidone treatment of drug-related psychosis in patients with Parkinsonism |
002B23 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
002B48 |
José Antonio Molina [Espagne] ; Maria José Sainz-Artiga [Espagne] ; Talicia Fraile [Espagne] ; Félix Javier Jimenez-Jimenez [Espagne] ; Clara Villanueva [Espagne] ; Miguel Orti-Pareja [Espagne] ; Félix Bermeio-P [Espagne] | Pathologic gambling in Parkinson's disease : A behavioral manifestation of pharmacologic treatment? |
002B69 |
Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis] | Modafinil treatment of pramipexole-associated somnolence |
002B76 |
S. Frucht [États-Unis] ; S. Fahn [États-Unis] ; S. Chin [États-Unis] ; V. Dhawan [États-Unis] ; D. Eidelberg [États-Unis] | Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration |
002B83 |
Doron Merims [Israël] ; Ronit Galili-Mosberg [Israël] ; Eldad Melamed [Israël] | Is there addiction to levodopa in patients with Parkinson's disease? |
002B91 |
T. E. Kimber [Australie] ; P. D. Thompson [Australie] | Increased blink rate in advanced Parkinson's disease : A form of 'off'-period dystonia? |
002B94 |
A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease |
002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
002C21 |
C. G. Goetz [États-Unis] ; G. T. Stebbins [États-Unis] ; L. M. Blasucci [États-Unis] | Differential progression of motor impairment in levodopa-treated Parkinson's Disease |
002C23 |
N. L. W. Keijsers [Pays-Bas] ; M. W. I. M. Horstink [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; J. I. Hoff [Pays-Bas] ; C. C. A. M. Gielen [Pays-Bas] | Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks |
002C37 |
J. Kulisevsky [Espagne] ; C. Garcia-Sanchez [Espagne] ; M. L. Berthier [Espagne] ; M. Barbanoj [Espagne] ; B. Pascual-Sedano [Espagne] ; A. Gironell [Espagne] ; A. Estevez-Gonzalez [Espagne] | Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease : A two-year follow-up study of previously untreated patients |
002C45 |
H. Apaydin [Turquie] ; S. Ertan [Turquie] ; S. Özekmekci [Turquie] | Broad bean (Vicia faba) : A natural source of L-dopa : Prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations |
002C52 |
E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche] | Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease |
002C53 |
K. Ray Chaudhuri [Royaume-Uni] ; M. T. M. Hu [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] | Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK |
002C54 |
J. H. Friedman [États-Unis] ; S. A. Factor | Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease |
002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
002C84 |
| Dyskinesias |
002C97 |
J. L. Montastruc [France] ; Olivier Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
002C98 |
S. A. Factor [États-Unis] ; E. S. Molho [États-Unis] | Transient benefit of amantadine in Parkinson's disease : The facts about the myth |
002D01 |
B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
002D03 |
M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France] | The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease |
002D04 |
W. J. Weiner [États-Unis] | The initial treatment of Parkinson's disease should begin with levodopa |
002D07 |
J. E. Ahlskog [États-Unis] ; R. J. Uitti [États-Unis] ; M. K. O'Connor [États-Unis] ; D. M. Maraganore [États-Unis] ; J. Y. Matsumoto [États-Unis] ; K. F. Stark [États-Unis] ; M. F. Turk [États-Unis] ; O. L. Burnett [États-Unis] | The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease |
002D09 |
S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne] | The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations |
002D22 |
A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Selegiline-induced postural hypotension in Parkinson's disease : A longitudinal study on the effects of drug withdrawal |
002D32 |
A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges |
002D34 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] ; C. Jacques [États-Unis] ; M. Rosenfeld [États-Unis] | Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease |
002D35 |
J. M. Brotchie [Royaume-Uni] ; S. H. Fox [Royaume-Uni] | Quantitative assessment of dyskinesias in subhuman primates |
002D37 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] | Punding on L-dopa |
002D54 |
P. J. Bedard [Canada] ; P. J. Blanchet [Canada] ; D. Levesque [Canada] ; J.-J. Soghomonian [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; F. Calon [Canada] ; P. Falardeau [Canada] ; B. Gomez-Mancilla [Canada] ; J.-P. Doucet [Canada] ; G. S. Robertson [Canada] ; T. Dipaolo [Canada] | Pathophysiology of L-Dopa-induced dyskinesias |
002D60 |
L. E. Davis [États-Unis] ; J. C. Adair [États-Unis] | Parkinsonism from methanol poisoning : Benefit from treatment with anti-Parkinson drugs |
002D74 |
J. Kimber [Royaume-Uni] ; L. Watson ; C. J. Mathias | Neuroendocrine responses to levodopa in multiple system atrophy (MSA) |
002D93 |
N. Giladi [Israël] ; E. Melamed [Israël] | Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism |
002D96 |
Olivier Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
002D97 |
R. K. B. Pearce [Royaume-Uni] | L-dopa and dyskinesias in normal monkeys |
002E02 |
F. Stocchi [Italie] ; C. Farina [Italie] ; G. Nordera [Italie] ; S. Ruggieri [Italie] | Implantable venous access system for apomorphine infusion in complicated Parkinson's disease |
002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
002E25 |
R. B. Innis [États-Unis] ; K. L. Marek [États-Unis] ; K. Sheff [États-Unis] ; S. Zoghbi [États-Unis] ; J. Castronuovo [États-Unis] ; A. Feigin [États-Unis] ; J. P. Seibyl [États-Unis] | Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT |
002E31 |
P. Brown [Royaume-Uni] ; A. Manson [Royaume-Uni] | Dyskinesias assessment and ambulatory devices |
002E67 |
E. Moro [Italie] ; A. Albanese [Italie, Suisse] | Apomorphine and levodopa challenge in patients with a focal midbrain lesion |
002E78 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; Olivier Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
002F15 |
N. Syed [États-Unis] ; J. Murphy [États-Unis] ; T. Jr Zimmerman [États-Unis] ; M. H. Mark [États-Unis] ; J. I. Sage [États-Unis] | Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease |
002F21 |
P. Van Den Munckhof [États-Unis] ; F. A. Lenz [États-Unis] ; T. N. Chase [États-Unis] ; L. V. Metman [États-Unis] | Square-wave action dystonia in Parkinson's disease |
002F25 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
002F26 |
Olivier Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
002F41 |
P. Hagell [Suède] ; P. Odin [Allemagne] ; E. Vinge [Suède] | Pregnancy in Parkinson's disease : A review of the literature and a case report |
002F51 |
P. G. Wasielewski [États-Unis] ; J. M. Burns [États-Unis] ; W. C. Koller [États-Unis] | Pharmacologic treatment of tremor |
002F57 |
E. J. Skalabrin [États-Unis] ; E. R. Jr Laws [États-Unis] ; J. P. Jr Bennett [États-Unis] | Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease |
002F74 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
002F86 |
N. R. Hughes [Royaume-Uni] ; A. T. Mcknight [Royaume-Uni] ; G. N. Woodruff [Royaume-Uni] ; M. P. Hill [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism |
002F89 |
P. Krack [France] ; Pierre Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; Alim-Louis Benabid [France] | Inhibition of levodopa effects by internal pallidal stimulation |
003011 |
J. D. O'Sullivan [Australie] ; C. M. Said [Australie] ; L. C. Dillon [Australie] ; M. Hoffman [Australie] ; A. J. Hughes [Australie] | Gait analysis in patients with Parkinson's disease and motor fluctuations : Influence of levodopa and comparison with other measures of motor function |
003027 |
J. S. Schneider [États-Unis] ; A. Pope-Coleman [États-Unis] ; M. Van Velson [États-Unis] ; F. Menzaghi [États-Unis] ; G. K. Lloyd [États-Unis] | Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
003038 |
A. P. Payne [Royaume-Uni] ; R. G. Sutcliffe [Royaume-Uni] ; J. M. Campbell [Royaume-Uni] ; G. Favor [Royaume-Uni] ; D. Russell [Royaume-Uni] ; N. K. Bennett [Royaume-Uni] ; D. J. Clarke [Royaume-Uni] ; R. Branton [Royaume-Uni] ; R. W. Davies [Royaume-Uni] ; E. Simpson [Royaume-Uni] ; C. Tsang [Royaume-Uni] ; R. H. Baxendale [Royaume-Uni] | Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts |
003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
003046 |
C. W. Olanow [États-Unis] ; C. Mytilineou [États-Unis] ; W. Tatton [États-Unis] | Current status of selegiline as a neuroprotective agent in Parkinson's disease |
003052 |
P. A. Lewitt [États-Unis] | Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease |
003059 |
H. H. Fernandez [États-Unis] ; R. Durso [États-Unis] | Clozapine for dopaminergic-induced paraphilias in Parkinson's disease |
003082 |
T. Van Laar [Pays-Bas] ; G.-J. Lammers [Pays-Bas] ; R. A. C. Roos [Pays-Bas] ; J. J. Gerritsen [Pays-Bas] ; A. E. Meinders [Pays-Bas] | Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion |
003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
003088 |
J. M. Brotchie [Royaume-Uni] | Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease |
003094 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; P. Van Den Munckhof [États-Unis] ; P. Del Dotto [États-Unis] ; R. Natte [États-Unis] ; T. N. Chase [États-Unis] | A trial of dextromethorphan in Parkinsonian patients with motor response complications |
003095 |
P. A. Lapchak [États-Unis] | A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease |
003096 |
R. A. Hauser [États-Unis] ; E. Molho [États-Unis] ; H. Shale [États-Unis] ; S. Pedder [États-Unis] ; E. E. Dorflinger [États-Unis] | A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients |
003097 |
R. B. Jr Dewey [États-Unis] ; D. M. Maraganore [États-Unis] ; J. E. Ahlskog [États-Unis] ; J. Y. Matsumoto [États-Unis] | A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease |
003118 |
E. Dupont [Danemark] ; J.-M. Burgunder [Suisse] ; L. J. Findley [Royaume-Uni] ; J.-E. Olsson [Suède] ; E. Dorflinger [États-Unis] | Tolcapone added to levodopa in stable parkinsonian patients : A double-blind placebo-controlled study |
003121 |
E. J. Pappert [États-Unis] ; J. W. Lipton [États-Unis] ; C. G. Goetz [États-Unis] ; Z. D. Ling [États-Unis] ; G. T. Stebbins [États-Unis] ; P. M. Carvey [États-Unis] | The stability of carbidopa in solution |
003125 |
P. Lewitt [États-Unis] ; D. Oakes [États-Unis] ; L. Cui [États-Unis] | The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol |
003127 |
J. P. Larsen [Norvège] ; J. Boas [Danemark] | The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : An interim analysis of a Norwegian-Danish 5-year study |
003128 |
L. Rioux [États-Unis] ; P. A. Frohna [États-Unis] ; J. N. Joyce [États-Unis] ; J. S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
003129 |
F. Lobbezoo [Canada] ; G. J. Lavigne [Canada] ; R. Tanguay [Canada] ; J. Y. Montplaisir [Canada] | The effect of the catecholamine precursor L-dopa on sleep bruxism : A controlled clinical trial |
003146 |
A. Burleigh-Jacobs [États-Unis] ; F. B. Horak [États-Unis] ; J. G. Nutt [États-Unis] ; J. A. Obeso [Espagne] | Step initiation in Parkinson's disease : Influence of levodopa and external sensory triggers |
003151 |
J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; S. Ahtila [Finlande] ; P. Tuomainen [Finlande] ; H. Ter V Inen [Finlande] | Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease |
003152 |
M. Zappia [Italie] ; R. Montesanti [Italie] ; R. Colao [Italie] ; D. Branca [Italie] ; G. Nicoletti [Italie] ; U. Aguglia [Italie] ; A. Quattrone [Italie] | Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease |
003194 |
J. G. Nutt [États-Unis] ; J. H. Carter [États-Unis] ; E. S. Lea [États-Unis] ; W. R. Woodward [États-Unis] | Motor fluctuations during continuous Levodopa infusions in patients with Parkinson's disease |
003196 |
M. Gu [Royaume-Uni] ; M. T. Gash [Royaume-Uni] ; J. M. Cooper [Royaume-Uni] ; G. K. Wenning [Royaume-Uni] ; S. E. Daniel [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] | Mitochondrial respiratory chain function in multiple system atrophy |
003205 |
I. Ziv [Israël] ; R. Zilkha-Falb [Israël] ; D. Offen [Israël] ; A. Shirvan [Israël] ; A. Barzilai [Israël] ; E. Melamed [Israël] | Levodopa induces apoptosis in cultured neuronal cells : A possible accelerator of nigrostriatal degeneration in Parkinson's disease? |
003209 |
A. H. Rajput [Canada] ; M. E. Fenton [Canada] ; S. Birdi [Canada] ; R. Macaulay [Canada] | Is levodopa toxic to human substantia nigra? |
003218 |
K. Ikeda [Japon] ; M. Kinoshita [Japon] ; K. Aoki [Japon] ; A. Tomatsuri [Japon] | Hydrocephalic parkinsonism due to Paget's disease of bone : Dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy |
003232 |
L. A. Smith [Royaume-Uni] ; A. Gordin [Finlande] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets |
003238 |
A. Rajput [États-Unis] ; A. Kishore [Canada] ; B. Snow [Canada] ; C. F. Bolton [Canada] ; A. H. Rajput [Canada] | Dopa-responsive, nonprogressive, juvenile parkinsonism : Report of a case |
003254 |
R. Pahwa [États-Unis] ; K. Lyons [États-Unis] ; D. Mcguire [États-Unis] ; P. Silverstein [États-Unis] ; F. Zwiebel [États-Unis] ; M. Robischon [États-Unis] ; W. C. Koller [États-Unis] | Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures |
003261 |
G. Gomez Arevalo [Argentine] ; R. Jorge [Argentine] ; S. Garcia [Argentine] ; O. Scipioni [Argentine] ; O. Gershanik [Argentine] | Clinical and pharmacological differences in early- versus late-onset Parkinson's disease |
003294 |
N. Andreu [France] ; C. Damase-Michel [France] ; J.-M. Senard [France] ; Olivier Rascol [France] ; J.-L. Montastruc [France] | A dose-ranging study of selegiline in patients with Parkinson's disease : Effect on platelet monoamine oxidase activity |
003319 |
C. Raftopoulos [Belgique] ; S. Dethy ; M. A. Laute ; S. Goldman ; A. B. Naini ; S. Przedborski ; J. Hildebrand | Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration |
003328 |
A. Tan [États-Unis] ; M. Salgado [États-Unis] ; S. Fahn [États-Unis] | Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa |
003335 |
F. Picard [France] ; A. De Saint-Martin [France] ; E. Salmon [Belgique] ; E. Hirsch [France] ; C. Marescaux [France] | Postencephalitic stereotyped involuntary movements responsive to L-Dopa |
003336 |
R. Pahwa [États-Unis] ; J. Marjama [États-Unis] ; D. Mcguire [États-Unis] ; K. Lyons [États-Unis] ; F. Zwiebel ; P. Silverstein ; R. Ward ; W. C. Koller [États-Unis] | Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study |
003352 |
E. J. Pappert [États-Unis] ; C. Buhrfiend ; J. W. Lipton ; P. M. Carvey ; G. T. Stebbins ; C. G. Goetz | Levedopa stability in solution : time course, environmental effects, and practical recommendations for clinical use |
003377 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease |
003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
003397 |
G. Geminiani [Italie] ; V. Fetoni [Italie] ; S. Genitrini [Italie] ; P. Giovannini [Italie] ; F. Tamma [Italie] ; T. Caraceni [Italie] | Cabergoline in Parkinson's disease complicated by motor fluctuations |
003407 |
D.-E. Shan [Taïwan] ; S.-Y. Kwan [Taïwan] ; H.-H. Ho [Taïwan] ; M.-S. Su [Taïwan] | Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy |
003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
003415 |
A. Benazzouz [France] ; T. Boraud [France] ; J. Feger [France] ; P. Burbaud [France] ; B. Bioulac [France] ; C. Gross [France] | Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates : A comparison with L-dopa treatment |
003416 |
P. J. Blanchet [États-Unis] ; L. V. Metman [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Acute pharmacologic blockade of dyskinesias in Parkinson's disease |
003435 |
W. Diaz Neira [Espagne] ; V. Sanchez ; M. A. Mena ; J. G. De Yebenes | The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease |
003449 |
J. C. Garcia-Monco [Espagne] ; A. Padierna ; M. G. Beldarrain | Selegiline, fluoxetine, and depression in Parkinson's disease |
003462 |
T. Van Laar [Pays-Bas] ; E. N. H. Jansen ; C. Neef ; M. Danhof ; R. A. C. Roos | Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease : a study of five different suppositories |
003463 |
S. Przedborski [Belgique] ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand [Belgique] | Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans |
003475 |
R. A. Maricle [États-Unis] ; J. G. Nutt ; J. H. Carter | Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion : preliminary findings |
003477 |
G. Fabbrini [Italie] ; F. Baronti ; S. Ruggieri ; G. L. Lenzi | Meningioma-induced loss of antiparkinsonian response to levodopa |
003501 |
T. L. Davis [États-Unis] ; M. Roznoski ; R. S. Burns | Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenalalanine/carbidopa and selegiline |
003503 |
R. Djaldetti [Israël] ; M. Koren ; ILAN ZIV ; A. Achiron ; ELDAD MELAMED | Effect of cisapride on response fluctuations in Parkinson's disease |
003506 |
C. E. Clarke [Royaume-Uni] | Does levodopa therapy delay death in Parkinson's disease ? A review of the evidence |
003527 |
S. T. Gancher [États-Unis] ; J. G. Nutt [États-Unis] ; W. R. Woodward | Apomorphine infusional therapy in Parkinson's disease : clinical utility and lack of tolerance |
003528 |
S. Przedborski [États-Unis] ; V. Jackson-Lewis ; S. Fahn | Antiparkinsonian therapies and brain mitochondrial complex I activity |
003539 |
G. K. Wenning [Royaume-Uni] ; M. T. O'Connell ; P. N. Patsalos ; N. P. Quinn | A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease |
003540 |
A. M. Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
003588 |
G. Pezzoli [Italie] ; E. Martignoni ; C. Pacchetti ; V. A. Angeleri ; P. Lamberti ; A. Muratorio ; U. Bonuccelli ; M. De Mari ; N. Foschi ; E. Cossutta ; F. Nicoletti ; F. Giammona ; M. Cansei [Italie] ; G. Scarlato [Italie] ; T. Caraceni ; E. Moscarelli | Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study |
003594 |
Olivier Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. Rascol | Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
003598 |
L. V. Metman [États-Unis] ; V. H. Sethy ; J. R. Roberts ; D. Bravi ; J. I. Hoff ; M. M. Mouradian ; T. N. Chase | Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in Parkinson's disease |
003614 |
L. Verhagen Metman [États-Unis] ; J. Hoff ; M. M. Mouradian ; T. N. Chase | Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa |
003655 |
R. A. Hauser [États-Unis] ; C. W. Olanow | orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease |
003662 |
D. Bravi [États-Unis] ; T. L. Davis ; M. M. Mouradian ; T. N. Chase | Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980 |
003672 |
C. Pacchetti [Italie] ; E. Martignoni [Italie] ; P. Bruggi [Italie] ; L. Godi [Italie] ; B. Aufdembrinke ; C. Miltenburger ; B. Voet ; G. Nappi [Italie] | Terguride in fluctuating Parkinsonian patients: a double-blind study versus placebo |
003676 |
S. B. Blunt [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine |
003677 |
A. J. Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern | Subcateneous apomorphine in Parkinson's disease: response to chronic administration for up to five years |
003680 |
B. Johnels [Suède] ; P. E. Ingvarsson [Suède] ; B. Holmberg ; M. Matousek [Suède] ; G. Steg [Suède] | Single-dose L-dopa response in early parkinson's disease : measurements with optoelectronic recording technique |
003713 |
G. J. Gomez Arevalo [Argentine] ; O. S. Gershanik | Modulator effect of clozapine on levodopa response in Parkinson's disease: a preliminary study |
003714 |
M. E. Giuffra [États-Unis] ; V. H. Sethy ; T. L. Davis ; M. M. Mouradian ; T. N. Chase | Milacemide therapy for Parkinson's disease |
003733 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
003734 |
P. Lamberti [Italie] ; M. De Mari ; G. Iliceto ; M. Caldarola ; L. Serlenga | Effect of L-dopa on oculogyric crises in a case of dopa-responsive dystonia |
003735 |
S. A. Factor [États-Unis] ; W. J. Weiner | Early combination therapy with bromocriptine and levodopa in Parkinson's disease |
003737 |
J. G. Nutt [États-Unis] ; J. H. Carter ; W. Woodward ; J. P. Hammerstad ; S. T. Gancher | Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions |
003753 |
B. Pardo [États-Unis] ; M. A. Mena [États-Unis] ; S. Fahn ; J. Garcia De Yebenes | Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line |
003754 |
U. Bonuccelli [Italie] ; P. Piccini [Italie] ; P. Del Dotto [Italie] ; G. Rossi ; G. U. Corsini ; A. Muratorio [Italie] | Apomorphine test for dopaminergic responsiveness: a dose assessment study |
003759 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
003761 |
M. Vidailhet [France] ; C. Bouchard [France] ; P. J. Jedynak [France] ; M. Serdaru [France] | Acute and long-term response to apomorphine in cranial dystonia |
003762 |
S. A. Factor [États-Unis] | Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease |
003794 |
M. A. Mena [Espagne] ; B. Pardo ; M. J. Casarejos ; S. Fahn ; J. G. De Yebenes | Neurotoxicity of levodopa on catecholamine-rich neurons |
003799 |
M. R. Luquin [Espagne] ; O. Scipioni ; J. Vaamonde ; O. Gershanik ; J. A. Obeso | Levopoda-induced dyskinesias in Parkinson's disease : clinical and pharmacological classification |
003800 |
J.-F. De Saint Victor [France] ; C.-L. Gervason | Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine |
003801 |
M Contin [Italie] ; R. Riva ; P. Martinelli ; A. Baruzzi | Kinetic-dynamic relationship of oral levopoda : possible biphasic response after sequential doses in Parkinson's disease |
003804 |
F. Stocchi [Italie] ; S. Ruggieri ; A. Carta ; J. Ryatt ; N. Quinn ; P. Jenner ; C. D. Marsden ; A. Agnoli | Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease |
003807 |
S. Przedborski [Belgique] ; A. Liard ; J. Hildebrand | Induction of mania by apomorphine in a depressed Parkinsonian patient |
003812 |
M. J. Steiger [Royaume-Uni] ; M. Pires ; F. Scaravilli ; N. P. Quinn ; C. D. Marsden | Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration |
003816 |
E. Pourcher [Canada] ; B. Gomez-Mancilla ; P. J. Bedard | Ethosuximide and tremor in Parkinson's disease : a pilot study |
003818 |
M. Emre [Suisse] ; U. K. Rinne ; A. Rascol ; A. Lees ; Yves Agid [France] ; X. Lataste | Effects of a selective partial D1 agonist, CY 208-243, in De Novo patients with Parkinson disease |
003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
003852 |
M. J. Steiger ; N. P. Quinn ; C. D. Marsden | Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease |
003864 |
R. Kurlan [États-Unis] ; M. H. Kim ; D. M. Gash | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys : assessment with a new rating scale for monkey parkinsonism |
003865 |
M. J. Steiger ; N. P. Quinn ; B. Toone ; C. D. Marsden | Off-period screaming accompanying motor fluctuations in Parkinson's disease |
003871 |
F. Dagani [Italie] ; R. Ferrari ; J. I. Anderson ; T. N. Chase | L-Dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria |
003885 |
L. L. Edwards ; R. F. Pfeiffer ; E. M. M. Quigley ; R. Hofman ; M. Balluff | Gastrointestinal symptoms in Parkinson's disease |
003891 |
P. Giovannini ; I. Piccolo ; S. Genitrini ; P. Soliveri ; F. Girotti ; G. Geminiani ; G. Scigliano ; T. Caraceni | Early-onset Parkinson's disease |
003904 |
S. T. Gancher ; J. G. Nutt ; W. R. Woodward | Absorption of apomorphine by various routes in parkinsonism |
003939 |
M. A. Menza ; J. Sage ; E. Marshall ; R. Cody ; R. Duvoisin | Mood changes and on-off phenomena in Parkinson's disease |
003943 |
S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Induction of chorea and dystonia in parkinsonian primates |
003954 |
U. J. Povlsen ; H. Pakkenberg | Effect of intravenous injection of biperiden and clonazepam in dystonia |
003955 |
J. Vaamonde ; M. R. Luquin ; J. A. Obeso | Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease |
003966 |
Werner Poewe [Autriche] ; G. Luef ; B. Kleedorfer ; M. Emre | Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease |
003972 |
A. R. Crossman | A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment |
003986 |
R. J. Coleman ; K. W. Lange ; N. P. Quinn ; A. E. Loper ; J. V. Bondi ; M. Hitchens ; S. M. Stahl ; C. D. Marsden | The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+ PHNO): preliminary results |
003996 |
D. T. Dexter ; P. Jenner ; C. D. Marsden | Oxyferriscarbone elevates the total iron content of blood but not brain |
003A00 |
S. Gimenez-Roldan ; D. Mateo ; M. Martin | Life-threatening cranial dystonia following trihexyphenidyl with drawal |
003A08 |
E. Mohr ; G. Fabbrini ; J. Williams ; J. Schlegel ; C. Cox ; P. Fedio ; T. N. Chase | Dopamine and memory function in Parkinson's disease |
003A14 |
R. F. Pfeiffer ; L. H. Herrera ; C. S. Glaeske ; R. E. Hofman | CQP A01-403 in Parkinson's disease: an open-label pilot study |
003A18 |
J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
003A21 |
R. F. Pfeiffer ; E. L. Sucha | "On-off"-Induced lethal hyperthermia |
003A30 |
S. Rose ; P. Jenner ; C. D. Marsden | The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats |
003A43 |
G. Pezzoli ; S. Tesei ; C. Ferrante ; E. Cossutta ; A. Zecchinelli ; G. Scarlato | Madopar HBS in fluctuating Parkinsonian patients: two-year treatment |
003A45 |
O. S. Gershanik ; M. R. Luquin ; O. Scipioni ; J. A. Obeso | Isoniazid therapy in Parkinson's disease |
003A50 |
M. Hietanen ; H. Teravainen | Dementia and treatment with L-dopa in Parkinson's disease |
003A78 |
J. L. Montastruc ; P. Celsis ; A. Agniel ; J. F. Demonet ; B. Doyon ; M. Puel ; J. P. Marc-Vergnes ; A. Rascol | Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease: lack of correlation with clinical or neuropsychological improvements |
003A96 |
F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; C. D. Marsden ; S. M. Stahl | Antiparkinsonian activity of a single oral dose of PHNO |
003A97 |
N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden | Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset |